Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 | Q02750 | 17/20 | 0.85 |
| ▸ | MAP2K2 | P36507 | 8/20 | 0.85 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.85 |
| ▸ | BRAF | P15056 | 1/20 | 0.85 |
| ▸ | MAP2K5 | Q13163 | 1/20 | 0.85 |
| ▸ | PIM1 | P11309 | 1/20 | 0.70 |
| ▸ | CAMK2B | Q13554 | 1/20 | 0.70 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.64 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.64 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.64 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.64 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.64 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.64 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.64 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.64 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.64 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.64 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4859890 | 1.00 | MAP2K1 (0.85) | MAP2K1MAP2K2MAPK1BRAFMAP2K5 | |
| SCHEMBL7051638 | 0.96 | MAP2K1 (0.79) | MAP2K1MAP2K2MAPK1BRAFMAP2K5 | |
| SCHEMBL4860675 | 0.93 | MAP2K1 (0.80) | MAP2K1MAP2K2MAPK1BRAFMAP2K5 | |
| SCHEMBL4853444 | 0.92 | MAP2K1 (0.72) | MAP2K1MAP2K2MAPK1BRAFMAP2K5 | |
| SCHEMBL4859973 | 0.92 | MAP2K1 (0.82) | MAP2K1MAP2K2MAPK1BRAFMAP2K5 | |
| SCHEMBL16366052 | 0.92 | MAP2K1 (0.82) | MAP2K1MAP2K2MAPK1BRAFMAP2K5 | |
| Mirdametinib SCHEMBL29352748 | 0.92 | MAP2K1 (1.00) | MAP2K1MAP2K2MAPK1BRAFMAP2K5 | |
| Mirdametinib SCHEMBL172904 | 0.92 | MAP2K1 (1.00) | MAP2K1MAP2K2MAPK1BRAFMAP2K5 | |
| Mirdametinib SCHEMBL29358470 | 0.92 | MAP2K1 (1.00) | MAP2K1MAP2K2MAPK1BRAFMAP2K5 | |
| Mirdametinib SCHEMBL895854 | 0.92 | MAP2K1 (1.00) | MAP2K1MAP2K2MAPK1BRAFMAP2K5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180214449-A1 | CANCER THERAPY USING JAK INHIBITOR IN COMBINATION WITH MAPK INHIBITORS | UBRX, INC. | 2018-08-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180214449-A1 | CANCER THERAPY USING JAK INHIBITOR IN COMBINATION WITH MAPK INHIBITORS | JAK2, JAK1, JAK3 | MAP2K1 57/4885MAP2K2 52/4885MAPK1 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.